EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
Open Access
- 22 January 2018
- journal article
- letter
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (1), 1-5
- https://doi.org/10.1038/s41408-017-0045-4
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Polycomb repressive complexes in hematological malignanciesBlood, 2017
- DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemiaAmerican Journal of Hematology, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2016
- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsNature Communications, 2016
- Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaBlood Cancer Journal, 2016
- ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsLeukemia, 2014
- Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaJournal of Clinical Oncology, 2013
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene RepressionCancer Cell, 2012
- Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasmsLeukemia, 2011